The effects of chronic repetitive transcranial magnetic stimulation on glutamate and gamma-aminobutyric acid in rat brain

Brain Research

Volumn 1260, Issue , 2009, Pages 94-99

  Yue, Li ^a   Xiao lin, Huo ^a   Tao, Song ^a  

^a INSTITUTE OF ELECTRICAL ENGINEERING   (China)

Author keywords

Gamma aminobutyric acid; Glutamate; Psychiatric disorder; Transcranial magnetic stimulation

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; NEUROTRANSMITTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HYPOTHALAMUS; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TRANSCRANIAL MAGNETIC STIMULATION; ANIMAL; MESENCEPHALON; METABOLISM; PHYSIOLOGY; RANDOMIZATION;

RATTUS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; HYPOTHALAMUS; MALE; MESENCEPHALON; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 61549120431     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.01.009     Document Type: Article

References (29)

1. Aydin-Abidin S., Trippe J., Funke K., Eysel U.T., and Benali A. High- and low-frequency repetitive transcranial magnetic stimulation differentially activates c-Fos and zif268 protein expression in the rat brain. Exp. Brain Res. 188 (2008) 249-261
2. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., and Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32 (2007) 1888-1902
3. Carroll F.I. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction. Ann. N.Y. Acad. Sci. 1141 (2008) 221-232
4. Erhardt A., Sillaber I., Welt T., Muller M.B., Singewald N., and Keck M.E. Repetitive transcranial magnetic stimulation increases the release of dopamine in the nucleus accumbens shell of morphine-sensitized rats during abstinence. Neuropsychopharmacology 29 (2004) 2074-2080
5. Fregni F., and Pascual-Leone A. Technology insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS. Nat. Clin. Pract. Neurol. 3 (2007) 383-393
6. George M.S., Wassermann E.M., and Post R.M. Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. J. Neuropsychiatry Clin. Neurosci. 8 (1996) 373-382
7. George M.S., Nahas Z., Kozel F.A., Li X., Denslow S., Yamanaka K., Mishory A., Foust M.J., and Bohning D.E. Mechanisms and state of the art of transcranial magnetic stimulation. J. ECT 18 (2002) 170-181
8. Harrison P.J., McLaughlin D., and Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 337 (1991) 450-452
9. Hausmann A., Marksteiner J., Hinterhuber H., and Humpel C. Magnetic stimulation induces neuronal c-fos via tetrodotoxin-sensitive sodium channels in organotypic cortex brain slices of the rat. Neurosci. Lett. 310 (2001) 105-108
10. Hedges D.W., Salyer D.L., Higginbotham B.J., Lund T.D., Hellewell J.L., Ferguson D., and Lephart E.D. Transcranial magnetic stimulation (TMS) effects on testosterone, prolactin, and corticosterone in adult male rats. Biol. Psychiatry 51 (2002) 417-421
11. Hedges D.W., Massari C., Salyer D.L., Lund T.D., Hellewell J.L., Johnson A.C., and Lephart E.D. Duration of transcranial magnetic stimulation effects on the neuroendocrine stress response and coping behavior of adult male rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 633-638
12. Kanno M., Matsumoto M., Togashi H., Yoshioka M., and Mano Y. Effects of repetitive transcranial magnetic stimulation on behavioral and neurochemical changes in rats during an elevated plus-maze test. J. Neurol. Sci. 211 (2003) 5-14
13. Keck M.E., Engelmann M., Muller M.B., Henniger M.S., Hermann B., Rupprecht R., Neumann I.D., Toschi N., Landgraf R., and Post A. Repetitive transcranial magnetic stimulation induces active coping strategies and attenuates the neuroendocrine stress response in rats. J. Psychiatr. Res. 34 (2000) 265-276
14. Keck M.E., Welt T., Post A., Muller M.B., Toschi N., Wigger A., Landgraf R., Holsboer F., and Engelmann M. Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects. Neuropsychopharmacology 24 (2001) 337-349
15. Kendell S.F., Krystal J.H., and Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets 9 (2005) 153-168
16. Kerwin R., Patel S., and Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39 (1990) 25-32
17. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., and Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 7 Suppl 1 (2002) S71-S80
18. Lacerda A.L., Nicoletti M.A., Brambilla P., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., and Soares J.C. Anatomical MRI study of basal ganglia in major depressive disorder. Psychiatry Res. 124 (2003) 129-140
19. Palomino A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., Gonzalez-Garcia G., and Matute C. Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophr. Res. 95 (2007) 174-178
20. Petty F. GABA and mood disorders: a brief review and hypothesis. J. Affect. Disord. 34 (1995) 275-281
21. Post A., and Keck M.E. Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms?. J. Psychiatr. Res. 35 (2001) 193-215
22. Reynolds G.P., and Harte M.K. The neuronal pathology of schizophrenia: molecules and mechanisms. Biochem. Soc. Trans. 35 (2007) 433-436
23. Reynolds G.P., Czudek C., and Andrews H.B. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol. Psychiatry 27 (1990) 1038-1044
24. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., Griffey K.I., Tizzano J.P., Monn J.A., McKinzie D.L., and Schoepp D.D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193 (2007) 121-136
25. Sanacora G., Mason G.F., and Krystal J.H. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit. Rev. Neurobiol. 14 (2000) 23-45
26. Sanacora G., Fenton L.R., Fasula M.K., Rothman D.L., Levin Y., Krystal J.H., and Mason G.F. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol. Psychiatry 59 (2006) 284-286
27. Simpson M.D., Slater P., and Deakin J.F. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biol. Psychiatry 44 (1998) 423-427
28. Thomson F., and Craighead M. Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33 (2008) 691-707
29. Zhang X., Mei Y., Liu C., and Yu S. Effect of transcranial magnetic stimulation on the expression of c-Fos and brain-derived neurotrophic factor of the cerebral cortex in rats with cerebral infarct. J. Huazhong Univ. Sci. Tech. Med. Sci. 27 (2007) 415-418